Intranasal fentanyl: From pharmacokinetics and bioavailability to current treatment applications

Expert Review of Anticancer Therapy

Volumn 10, Issue 7, 2010, Pages 1009-1021

  Panagiotou, Irene ^a   Mystakidou, Kyriaki ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

acute pain; breakthrough pain; cancer; fentanyl; intranasal; postoperative pain

Indexed keywords

ALFENTANIL; BUPRENORPHINE; BUTORPHANOL; FENTANYL; FENTANYL CITRATE; INSTANYL; MORPHINE; MORPHINE SULFATE; OXYCODONE; SUFENTANIL; UNCLASSIFIED DRUG; NARCOTIC AGENT;

ANALGESIA; ANALGESIC ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BREATHING RATE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSCIOUSNESS LEVEL; CONSTIPATION; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG FORMULATION; DYSGEUSIA; EUPHORIA; GASTROINTESTINAL ABSORPTION; HUMAN; HYPOTENSION; LIPOPHILICITY; NAUSEA; NEUROPATHIC PAIN; NOSE IRRITATION; NOSE MUCOSA; NOSE ULCER; OXYGEN SATURATION; PAIN; PAIN ASSESSMENT; PATIENT SATISFACTION; PH; PLASMA CLEARANCE; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SKIN PAIN; SOMNOLENCE; TOOTH EXTRACTION; VERTIGO; WOUND CARE; ADULT; AGED; BIOAVAILABILITY; INTRADERMAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MOUTH MUCOSA; NEBULIZER; NEOPLASM; NEURALGIA; ORAL DRUG ADMINISTRATION; PAIN, POSTOPERATIVE; PATHOPHYSIOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; AGED; BIOLOGICAL AVAILABILITY; FENTANYL; HUMANS; MIDDLE AGED; MOUTH MUCOSA; NARCOTICS; NASAL MUCOSA; NEBULIZERS AND VAPORIZERS; NEOPLASMS; NEURALGIA; PAIN; PAIN, POSTOPERATIVE; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954886236     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.77     Document Type: Review

References (53)

1. Mystakidou K, Katsouda E, Tsilika E, Parpa E, Vlachos L. Transdermal therapeutic fentanyl system. In vivo 18, 633-642 (2004).
2. Trandermal fentanyl: new preparation. An alternative to morphine. Prescrire Int. 37, 137-140 (1998).
3. Peng P, Sandler A. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 90, 576-599 (1999).
4. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.Clin. Pharmacokinet. 38, 59-89 (2000).
5. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81, 129-134 (1999).
6. Mercadante S, Radbruch L, Caraceni A et al.; for the steering committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough pain): consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94, 832-839 (2000).
7. Svendsen KB, Andersen S, Arnason S et al. Breakthrough pain in malignant and non-malignant diseases: A review of prevalence, characteristics and mechanisms. Eur. J. Pain 9, 195-206 (2005).
8. Portenoy RK, Bennett DS, Rauck R et al. Prevalence and characteristics of breakthrough pain in opioid treated patients with chronic noncancer pain. J. Pain 7, 583-591 (2006).
9. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat. Med. 15, 243-246 (2001).
10. Klepstad P, Kaasa S, Cherny N; for the Research Steering Committee of the European Association for Palliative Care. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat. Med. 19, 477-484 (2005).
11. Hanks GW, de Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer 84, 587-593 (2001).
12. Collins SL, Faura CC, Moore RA, McQuay HJ. Peak plasma concentrations after oral morphine: a systematic review. J. Pain Symptom Manage. 16, 388-402 (1998).
13. Mystakidou K, Katsouda E, Parpa E, Vlahos L. Oral transmucosal fentanyl citrate: Overview of clinical and pharmacological characteristics. Drug Delivery 13, 269-276 (2006).
14. Coluzzi PH, Schwartzberg L, Conroy JD et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91, 123-130 (2001).
15. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo- controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain 22, 805-811 (2006).
16. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today 44, 41-54 (2008).
17. Simpson D, Messina J, Xie F, Hale M. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 29, 588-601 (2007). (Pubitemid 47016640)
18. Darwish M, Tempero K, Kirby M, Thompson J. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT)1080 pg versus oral transmucosal fentanyl citrated 1600 pg and dose proportionality of FEBT 270 to 1300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin. Ther. 28, 715-724 (2006).
19. Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J. Pain Symptom Manag. 30, 496-497 (2005).
20. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids in pain management in adults. Acta Anaesthesiol. Scand. 46, 759-770 (2002).
21. Striebel HW, Kramer J, Lubmann I et al. Pharmakokinetische studie zur intranasalen gabe von fentanyl. Der Schmerz. 7, 122-125 (1993).
22. Lim SC, Paech MJ, Sunderland VB et al. Pharmacokinetics of nasal fentanyl. J. Pharm. Pract. Res. 33, 59-63 (2003).
23. Moksnes K, Fredheim OM, Klepstad P et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur. J. Clin. Pharmacol. 64, 497-502 (2008).
24. Christrup LL, Foster D, Popper L, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, cross-over study. Clin. Ther. 30, 469-481 (2008).
25. Foster D, Upton R, Christrup L, Popper L. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann. Pharmacother. 42, 1380-1387 (2008).
26. Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 90, 576-599 (1999).
27. Zeppetella G. An assessment of the safety, efficacy and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J. Pain Symptom Manage. 20, 253-258 (2000).
28. Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer- related breakthrough pain. Palliat. Med. 14, 57-58 (2000).
29. Paech MJ, Lim CB, Banks SL, Rucklidge MW, Doherty DA. A new formulation of nasal fentanyl spray for post-operative analgesia: a pilot study. Anaesthesia 58, 740-744 (2003).
30. Galinkin JL, Fazi LM, Cuy RM et al. Use of intranasal fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia. Anesthesiology 93, 1378-1383 (2000).
31. O'Neil G, Paech M, Wood F. Preliminary clinical use of a patient-controlled intranasal analgesia (PCINA) device. Anaesth. Intensive Care 25, 408-412 (1997).
32. Walker G, Wilcock A, Manderson C et al. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat. Med. 17, 219-221 (2003).
33. Kress HG, Ororiska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 fig for breakthrough pain in patients with cancer: a Phase III, multinational, randomised, double-blind, placebo-controlled, crossover trial with a 10-month, open label extension treatment period. Clin. Ther. 6, 1177-1191 (2009).
34. Mercadante S, Radbruch L, Davies A et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, cross-over trial. CMRO 25, 2805-2815 (2009).
35. Striebel HM, Oelmann T, Spies C, Rieger A, Schwagmeier R. Patient- controlled intranasal analgesia: a method for noninvasive postoperative pain management. Anesth. Analg. 83, 548-551 (1996).
36. Striebel HW, Pommerening J, Rieger A. Intranasal fentanyl titration for postoperative pain management in an unselected population. Anaesthesia 48, 753-757 (1993).
37. Striebel HW, Koenings D, Kramer J. Postoperative pain management by intranasal demand-adapted fentanyl titration. Anesthesiology 77, 281-285 (1992).
38. Striebel HW, Olmann T, Spies C, Brummer G. Patient-controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study. J. Clin. Anesth. 8, 4-8 (1996). (Pubitemid 26068220)
39. Toussaint S, Maidl J, Schwagmeier R, Striebel HW. Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief. Can. J. Anaesth. 47, 299-302 (2000).
40. Wong P, Chadwick FD, Karovits J. Intranasal fentanyl for postoperative analgesia after elective caesarean section. Anaesthesia 58, 818-819 (2003).
41. Finn J, Wright J, Fong J et al. A randomised crossover trial of patient controlled intranasal fentanyl and oral morphine for procedural wound care in adults with burns. Burns 30, 262-268 (2004).
42. Rickard C, O'Meara P, McGrail M et al. A randomized, controlled trial of intranasal fentanyl versus intravenous morphine in the pre-hospital setting. Am. J. Emerg Med. 25, 911-917 (2007).
43. Ueda W. Rhinorrhea by nasal fentanyl. Anesthesiology 95, 812-813 (2001).
44. Manjushree R, Lahiri A, Ghosh BR et al. Intranasal fentanyl provides adequate postoperative analgesia in pediatric patients. Can. J. Anaesth. 49, 190-193 (2002).
45. Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emerg. Med. (Fremantle WA). 14, 275-280 (2002).
46. Cole J, Shepherd M, Young P. Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia. Emerg. Med. Australas. 25, 395-400 (2009).
47. Borland ML, Clark LJ, Esson A. Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department. Emerg. Med. Australas. 20, 515-520 (2008).
48. Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Annals Emerg. Med. 49, 335-340 (2007).
49. Borland ML, Bergesio R, Pascoe EM et al. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: A randomized, double-blind, cross-over study. Burns 31, 831-837 (2005).
50. Yost J. Intranasal fentanyl and intravenous morphine did not differ for pain relief in children with closed long-bone fractures. Evid. Based Nurse. 11, 42 (2008).
51. Nave R, Sides EH, Colberg T et al. Pharmacokinetics on intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline. Presented at: EFIC. Lisbon, Portugal, 9-12 September 2009.
52. Nave R, Sides EH, Colberg T et al. Pharmacokinetics on intranasal fentanyl spray (INFS) in subjects with common cold. Presented at: EFIC. Lisbon, Portugal, 9-12 September 2009.
53. Christo PJ, Grabow TS, Raja SN. Opioid effectiveness, addiction, and depression in chronic pain. Adv. Phychosom. Med. 25, 123-137 (2004).